Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Cancer Inform ; 21: 11769351221086441, 2022.
Artigo em Inglês | MEDLINE | ID: mdl-35342286

RESUMO

Biomarkers, as measurements of defined biological characteristics, can play a pivotal role in estimations of disease risk, early detection, differential diagnosis, assessment of disease progression and outcomes prediction. Studies of cancer biomarkers are published daily; some are well characterized, while others are of growing interest. Managing this flow of information is challenging for scientists and clinicians. We sought to develop a novel text-mining method employing biomarker co-occurrence processing applied to a deeply indexed full-text database to generate time-interval-delimited biomarker co-occurrence networks. Biomarkers across 6 cancer sites and a cancer-agnostic network were successfully characterized in terms of their emergence in the published literature and the context in which they are described. Our approach, which enables us to find publications based on biomarker relationships, identified biomarker relationships not known to existing interaction networks. This search method finds relevant literature that could be missed with keyword searches, even if full text is available. It enables users to extract relevant biological information and may provide new biological insights that could not be achieved by individual review of papers.

2.
Histochem Cell Biol ; 154(5): 565-578, 2020 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-33079236

RESUMO

Lysosomal storage diseases are the most common cause of neurodegeneration in children. They are characterised at the cellular level by the accumulation of storage material within lysosomes. There are very limited therapeutic options, and the search for novel therapies has been hampered as few good small animal models are available. Here, we describe the use of light sheet microscopy to assess lipid storage in drug and morpholino induced zebrafish models of two diseases of cholesterol homeostasis with lysosomal dysfunction: First, Niemann-Pick type C disease (NPC), caused by mutations in the lysosomal transmembrane protein NPC1, characterised by intralysosomal accumulation of cholesterol and several other lipids. Second, Smith-Lemli-Opitz syndrome (SLOS), caused by mutations in 7-dehydrocholesterol reductase, which catalyses the last step of cholesterol biosynthesis and is characterised by intralysosomal accumulation of dietary cholesterol. This is the first description of a zebrafish SLOS model. We find that zebrafish accurately model lysosomal storage and disease-specific phenotypes in both diseases. Increased cholesterol and ganglioside GM1 were observed in sections taken from NPC model fish, and decreased cholesterol in SLOS model fish, but these are of limited value as resolution is poor, and accurate anatomical comparisons difficult. Using light sheet microscopy, we were able to observe lipid changes in much greater detail and identified an unexpected accumulation of ganglioside GM1 in SLOS model fish. Our data demonstrate, for the first time in zebrafish, the immense potential that light sheet microscopy has in aiding the resolution of studies involving lysosomal and lipid disorders.


Assuntos
Colesterol/análise , Modelos Animais de Doenças , Gangliosídeo G(M1)/análise , Doença de Niemann-Pick Tipo C/diagnóstico , Síndrome de Smith-Lemli-Opitz/diagnóstico , Peixe-Zebra , Animais , Colesterol/metabolismo , Gangliosídeo G(M1)/metabolismo , Lisossomos/metabolismo , Microscopia de Fluorescência , Doença de Niemann-Pick Tipo C/metabolismo , Síndrome de Smith-Lemli-Opitz/metabolismo
3.
J Bone Miner Res ; 35(3): 446-459, 2020 03.
Artigo em Inglês | MEDLINE | ID: mdl-31643098

RESUMO

High-resolution peripheral quantitative computed tomography (HR-pQCT) is a noninvasive imaging modality for assessing volumetric bone mineral density (vBMD) and microarchitecture of cancellous and cortical bone. The objective was to (1) assess fracture-associated differences in HR-pQCT bone parameters; and (2) to determine if HR-pQCT is sufficiently precise to reliably detect these differences in individuals. We systematically identified 40 studies that used HR-pQCT (39/40 used XtremeCT scanners) to assess 1291 to 3253 and 3389 to 10,687 individuals with and without fractures, respectively, ranging in age from 10.9 to 84.7 years with no comorbid conditions. Parameters describing radial and tibial bone density, microarchitecture, and strength were extracted and percentage differences between fracture and control subjects were estimated using a random effects meta-analysis. An additional meta-analysis of short-term in vivo reproducibility of bone parameters assessed by XtremeCT was conducted to determine whether fracture-associated differences exceeded the least significant change (LSC) required to discern measured differences from precision error. Radial and tibial HR-pQCT parameters, including failure load, were significantly altered in fracture subjects, with differences ranging from -2.6% (95% confidence interval [CI] -3.4 to -1.9) in radial cortical vBMD to -12.6% (95% CI -15.0 to -10.3) in radial trabecular vBMD. Fracture-associated differences reported by prospective studies were consistent with those from retrospective studies, indicating that HR-pQCT can predict incident fracture. Assessment of study quality, heterogeneity, and publication biases verified the validity of these findings. Finally, we demonstrated that fracture-associated deficits in total and trabecular vBMD and certain tibial cortical parameters can be reliably discerned from HR-pQCT-related precision error and can be used to detect fracture-associated differences in individual patients. Although differences in other HR-pQCT measures, including failure load, were significantly associated with fracture, improved reproducibility is needed to ensure reliable individual cross-sectional screening and longitudinal monitoring. In conclusion, our study supports the use of HR-pQCT in clinical fracture prediction. © 2019 American Society for Bone and Mineral Research.


Assuntos
Fraturas Ósseas , Densidade Óssea , Estudos Transversais , Fraturas Ósseas/diagnóstico por imagem , Humanos , Estudos Prospectivos , Rádio (Anatomia)/diagnóstico por imagem , Reprodutibilidade dos Testes , Estudos Retrospectivos
4.
PLoS One ; 11(6): e0157365, 2016.
Artigo em Inglês | MEDLINE | ID: mdl-27327661

RESUMO

The neuronal ceroid lipofuscinoses are a group of lysosomal storage disorders that comprise the most common, genetically heterogeneous, fatal neurodegenerative disorders of children. They are characterised by childhood onset, visual failure, epileptic seizures, psychomotor retardation and dementia. CLN3 disease, also known as Batten disease, is caused by autosomal recessive mutations in the CLN3 gene, 80-85% of which are a ~1 kb deletion. Currently no treatments exist, and after much suffering, the disease inevitably results in premature death. The aim of this study was to generate a zebrafish model of CLN3 disease using antisense morpholino injection, and characterise the pathological and functional consequences of Cln3 deficiency, thereby providing a tool for future drug discovery. The model was shown to faithfully recapitulate the pathological signs of CLN3 disease, including reduced survival, neuronal loss, retinopathy, axonopathy, loss of motor function, lysosomal storage of subunit c of mitochondrial ATP synthase, and epileptic seizures, albeit with an earlier onset and faster progression than the human disease. Our study provides proof of principle that the advantages of the zebrafish over other model systems can be utilised to further our understanding of the pathogenesis of CLN3 disease and accelerate drug discovery.


Assuntos
Epilepsia/complicações , Degeneração Neural/complicações , Lipofuscinoses Ceroides Neuronais/complicações , Peixe-Zebra/fisiologia , Animais , Apoptose/efeitos dos fármacos , Axônios/efeitos dos fármacos , Axônios/patologia , Comportamento Animal/efeitos dos fármacos , Encéfalo/anormalidades , Encéfalo/efeitos dos fármacos , Proliferação de Células/efeitos dos fármacos , Modelos Animais de Doenças , Eletroencefalografia , Epilepsia/patologia , Técnicas de Silenciamento de Genes , Gliose/patologia , Lisossomos/efeitos dos fármacos , Lisossomos/metabolismo , ATPases Mitocondriais Próton-Translocadoras/metabolismo , Morfolinos/farmacologia , Morfolinos/toxicidade , Atividade Motora/efeitos dos fármacos , Miocárdio/patologia , Degeneração Neural/patologia , Lipofuscinoses Ceroides Neuronais/patologia , Subunidades Proteicas/metabolismo , RNA Antissenso/metabolismo , Retina/efeitos dos fármacos , Retina/patologia , Análise de Sobrevida , Peixe-Zebra/embriologia , Proteínas de Peixe-Zebra/genética , Proteínas de Peixe-Zebra/metabolismo
5.
Biochim Biophys Acta ; 1852(10 Pt B): 2267-78, 2015 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-25937302

RESUMO

The neuronal ceroid lipofuscinoses are a group of severe and progressive neurodegenerative disorders, generally with childhood onset. Despite the fact that these diseases remain fatal, significant breakthroughs have been made in our understanding of the genetics that underpin these conditions. This understanding has allowed the development of a broad range of models to study disease processes, and to develop new therapeutic approaches. Such models have contributed significantly to our knowledge of these conditions. In this review we will focus on the advantages of each individual model, describe some of the contributions the models have made to our understanding of the broader disease biology and highlight new techniques and approaches relevant to the study and potential treatment of the neuronal ceroid lipofuscinoses. This article is part of a Special Issue entitled: "Current Research on the Neuronal Ceroid Lipofuscinoses (Batten Disease)".

6.
J Inherit Metab Dis ; 37(4): 483-95, 2014 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-24797558

RESUMO

The majority of human inborn errors of metabolism are fatal multisystem disorders that lack proper treatment and have a poorly understood mechanistic basis. Novel technologies are required to address this issue, and the use of zebrafish to model these diseases is an emerging field. Here we present the published zebrafish models of inborn metabolic diseases, discuss their validity, and review the novel mechanistic insights that they have provided. We also review the available methods for creating and studying zebrafish disease models, advantages and disadvantages of using this model organism, and successful examples of the use of zebrafish for drug discovery and development. Using a zebrafish to model inborn errors of metabolism in vivo, although still in its infancy, shows promise for a deeper understanding of disease pathomechanisms, onset, and progression, and also for the development of specific therapies.


Assuntos
Modelos Animais de Doenças , Erros Inatos do Metabolismo/patologia , Erros Inatos do Metabolismo/terapia , Peixe-Zebra , Animais , Descoberta de Drogas/métodos , Embrião não Mamífero , Humanos , Terapia de Alvo Molecular , Estudos de Validação como Assunto
7.
Autophagy ; 9(11): 1693-709, 2013 Nov 01.
Artigo em Inglês | MEDLINE | ID: mdl-23939015

RESUMO

Autophagy is responsible for the degradation of cytoplasmic components and organelles such as mitochondria. The selective degradation of damaged mitochondria by autophagy is termed mitophagy, and is an important quality control mechanism. Neurons, being highly specialized cells, are particularly susceptible to defects of autophagy. Impairments in mitochondrial function and their dynamics are present in many neurodegenerative diseases, and modulators of both mitochondrial physiology and autophagy present themselves as promising therapeutic targets. Zebrafish are now established as a valuable tool for disease modeling. A wide variety of genetic and molecular techniques can be employed to highlight pathogenic processes and dissect disease pathways. This review will explore the role that zebrafish have so far played in our understanding of mitophagy in neurodegeneration, and will discuss how they might be used to drive the wider mitophagy field forward.


Assuntos
Modelos Animais de Doenças , Mitofagia , Degeneração Neural/metabolismo , Peixe-Zebra/metabolismo , Animais , Humanos , Proteínas Mitocondriais/metabolismo , Degeneração Neural/patologia , Estresse Oxidativo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...